Johnson Controls stock price target raised to $130 by Wolfe Research

Johnson Controls (JCI) has demonstrated strong performance, reflected in Wolfe Research raising its price target to $130 with an Outperform rating, anticipating over $6 EPS by 2026 and an increased FY25 EPS guidance. This positive outlook is further supported by Moody's upgrading JCI's senior unsecured ratings to Baa1 and UBS reiterating a Buy rating, citing 70% earnings upside and a $9 billion share repurchase authorization. Despite trading near its 52-week high after a 33% six-month return, Oppenheimer downgraded the stock to Perform, citing valuation concerns and awaiting strategic review details, indicating a mixed analyst sentiment despite robust financial indicators.

Analysis

Johnson Controls (JCI) is exhibiting strong forward momentum, underscored by Wolfe Research raising its year-end 2026 price target to $130.00, citing a potential earnings trajectory exceeding $6.00 per share. This optimism is supported by expectations of an imminent fiscal year 2025 EPS guidance increase from approximately $3.60 to $3.70, driven by favorable foreign exchange, and anticipated mid-single-digit order growth. The company's fundamental health is further validated by a Moody's credit rating upgrade to Baa1, which reflects confidence in improving EBITDA margins and cash generation. Adding to the bullish case, UBS reiterated its buy rating, projecting a 70% earnings upside fueled by structural margin improvements and a substantial $9 billion increase in the share repurchase authorization. However, this positive outlook is tempered by valuation concerns following the stock's 33% return over the past six months. Oppenheimer's recent downgrade to Perform from Outperform directly highlights this issue, with the firm adopting a cautious stance pending details from the company's strategic review. The appointment of a new CHRO with transformation experience further signals that the company is at a strategic inflection point.

Key Decisions for Investors

• Investors with a bullish long-term outlook may find the confluence of positive analyst revisions, a major share buyback program, and a credit rating upgrade to be a strong signal to maintain or build positions.
• Given the stock is trading near 52-week highs and received a valuation-based downgrade from Oppenheimer, risk-averse or value-oriented investors should consider waiting for the company's strategic review and updated November guidance before committing new capital.
• Monitor upcoming earnings reports for confirmation of the expected mid-single-digit order growth and the delivery on the higher FY25 EPS guidance, as these will be critical for justifying the stock's current premium valuation.